DDInter410 DDInter899
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic ser
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Clomipramine {u} (Compound) resembles {v} (Compound) Adinazolam
Clomipramine {u} (Compound) resembles {v} (Compound) Thioridazine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Clomipramine {u} (Compound) binds {v} (Gene) CYP1A2
Clomipramine {u} (Compound) upregulates {v} (Gene) TGFBR2
Clomipramine {u} (Compound) palliates {v} (Disease) panic disorder
Clomipramine {u} (Compound) causes {v} (Side Effect) Uterine haemorrhage
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ammonium chloride
Clomipramine (Compound) resembles Adinazolam (Compound)
Clomipramine (Compound) resembles Thioridazine (Compound)
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Clomipramine (Compound) binds CYP1A2 (Gene)
Clomipramine (Compound) upregulates TGFBR2 (Gene)
Clomipramine (Compound) palliates panic disorder (Disease)
Clomipramine (Compound) causes Uterine haemorrhage (Side Effect)
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride